                         SEQUENCE LISTING

<110>  AMGEN INC.
 
<120>  METHODS FOR TREATING ATHEROSCLEROTIC CARDIOVASCULAR DISEASE WITH 
       LPA-TARGETED RNAi CONSTRUCTS

<130>  A-2694-WO-PCT

<150>  63/110,309
<151>  2020-11-05

<160>  12    

<170>  PatentIn version 3.5

<210>  1
<211>  18
<212>  RNA
<213>  Artificial Sequence

<220>
<223>  Synthetic polynucleotide

<400>  1
gccccuuauu guuauacg                                                     18


<210>  2
<211>  18
<212>  RNA
<213>  Artificial Sequence

<220>
<223>  Synthetic polynucleotide

<400>  2
cguauaacaa uaaggggc                                                     18


<210>  3
<211>  21
<212>  RNA
<213>  Artificial Sequence

<220>
<223>  Synthetic polynucleotide

<400>  3
cagccccuua uuguuauacg a                                                 21


<210>  4
<211>  21
<212>  RNA
<213>  Artificial Sequence

<220>
<223>  Synthetic polynucleotide

<400>  4
ucguauaaca auaaggggcu g                                                 21


<210>  5
<211>  21
<212>  RNA
<213>  Artificial Sequence

<220>
<223>  Synthetic modified polynucleotide


<220>
<221>  modified_base
<222>  (1)..(21)
<223>  combination of 2'-fluoro, 2'-O-methyl, inverted deoxyadenosine, 
       phosphorothioate linked ribonucleotides

<400>  5
cagccccuua uuguuauacg a                                                 21


<210>  6
<211>  21
<212>  RNA
<213>  Artificial Sequence

<220>
<223>  Synthetic modified polynucleotide


<220>
<221>  modified_base
<222>  (1)..(21)
<223>  combination of 2'-fluoro, 2'-O-methyl, phosphorothioate linked 
       ribonucleotides

<400>  6
ucguauaaca auaaggggcu g                                                 21


<210>  7
<211>  21
<212>  RNA
<213>  Artificial Sequence

<220>
<223>  Synthetic polynucleotide

<400>  7
gccccuuauu guuauacgau u                                                 21


<210>  8
<211>  21
<212>  RNA
<213>  Artificial Sequence

<220>
<223>  Synthetic polynucleotide

<400>  8
ucguauaaca auaaggggcu u                                                 21


<210>  9
<211>  21
<212>  RNA
<213>  Artificial Sequence

<220>
<223>  Synthetic modified polynucleotide


<220>
<221>  modified_base
<222>  (1)..(21)
<223>  combination of 2'-fluoro, 2'-O-methyl, inverted abasic, 
       phosphorothioate linked ribonucleotides

<400>  9
gccccuuauu guuauacgau u                                                 21


<210>  10
<211>  21
<212>  RNA
<213>  Artificial Sequence

<220>
<223>  Synthetic modified polynucleotide


<220>
<221>  modified_base
<222>  (1)..(21)
<223>  combination of 2'-fluoro, 2'-O-methyl, phosphorothioate linked 
       ribonucleotides

<400>  10
ucguauaaca auaaggggcu u                                                 21


<210>  11
<211>  21
<212>  RNA
<213>  Artificial Sequence

<220>
<223>  Synthetic modified polynucleotide


<220>
<221>  modified_base
<222>  (1)..(21)
<223>  combination of 2'-fluoro, 2'-O-methyl, inverted abasic, 
       phosphorothioate linked ribonucleotides

<400>  11
gccccuuauu guuauacgau u                                                 21


<210>  12
<211>  21
<212>  RNA
<213>  Artificial Sequence

<220>
<223>  Synthetic modified polynucleotide


<220>
<221>  modified_base
<222>  (1)..(21)
<223>  combination of 2'-fluoro, 2'-O-methyl, phosphorothioate linked 
       ribonucleotides

<400>  12
ucguauaaca auaaggggcu u                                                 21


